Close

Ionis Pharma (IONS) Completes Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease

June 22, 2017 7:01 AM EDT Send to a Friend
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the completion of enrollment in the Phase 1/2a randomized, placebo-controlled, dose escalation study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login